end-staged joint diseases
Conditions
Interventions
A:rivaroxaban application, 1 Week, qd
B:rivaroxaban application, 2 Week, qd
C:rivaroxaban application, 3 Week, qd
D:rivaroxaban application, 35 Day, qd
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Primary unilateral total knee artropasty; 2. Patients with Knee osteoartritis or Rheumatoid arthritis; 3. Able and willing to provide signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients combined with acute trauma, tumor, severe osteoporosis, other autoimmune diseases and severe muscle contracture deformity around hip/knee; 2. Previous history of neuro-vascular injury, vasculitis and diabetic foot etc; 3. Related thrombosis history, such as pulmonary embolism, thrombosis and deep vein thrombosis in recent three months; 4. Coagulation disorders, bleeding tendency or intraoperative active bleeding; 5. Clear history of iron metabolism disorders; 6. Sever comorbidities in brain cardiovascular system, liver (ALT or AST >2 high limitation of normal value), kidney (BUN >1.5 high limitation of normal value or Cr> 1.5 high limitation of normal value), endocrine, nerve, hematopoietic system or consciousness disorders; 7. Pregnancy or breast-feeding; 8. Allergy to the test drug and human serum albumin, severe allergies, drug or alcohol depedence; 9. Participate in other clinical trials in recent three months; 10. The surgeons believe the patients not suitable for this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| color Doppler Ultrasonic (CDU);thromboelastography;Routine coagulation tests; | — |
Secondary
| Measure | Time frame |
|---|---|
| ESR;CRP;incidence of ecchymosis;incidence of thromboembolism;The incidence of pulmonary embolism;major bleeding rate;Limb swelling;KSS;WOMAC; | — |
Countries
China
Contacts
Public ContactZhou Zong-ke
West China Hospital, Sichuan University
Outcome results
None listed